Chemo brain - A psychotropic drug phenomenon?

Medical Hypotheses

Volumn 70, Issue 3, 2008, Pages 572-577

  Jackson, Grace E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CARMUSTINE; CISPLATIN; CLOMIPRAMINE; CLOZAPINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; FLUOXETINE; IMIPRAMINE; LITHIUM; METHOTREXATE; MIANSERIN; NEUROLEPTIC AGENT; PAROXETINE; PERPHENAZINE; PHENOTHIAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; SULPIRIDE; THIORIDAZINE; VALPROIC ACID;

ARTICLE; BRAIN TUMOR; BREAST CANCER; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL DEATH; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; MULTIPLE CYCLE TREATMENT; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BRAIN; COGNITION DISORDERS; HUMANS; NEOPLASMS; NEUROPROTECTIVE AGENTS; PSYCHOTROPIC DRUGS;

EID: 38749115833     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.06.019     Document Type: Article

References (44)

1. Raffa R.B., Duong P.V., Finney J., et al. Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?. J Clin Pharm Ther 31 (2006) 129-138
2. Staat K., and Segatore M. The phenomenon of chemo brain. Clin J Oncol Nurs 9 6 (2005) 713-721
3. Tannock I.F., Ahles T.A., Ganz P.A., and Van Dam F.S. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22 11 (2004) 2233-2239
4. Fan H.G.M., Houede-Tchen N., Yi Q.L., et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 3 31 (2005) 8025-8032
5. Wefel J.S., Lenzi R., Theriault R.L., Davis R.N., and Meyers C.A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100 11 (2004) 2292-2299
6. Brown M.S., Stemmer S.M., Simon J.H., Cagnoni P.J., Sheeder J.L., et al. White matter disease induced by high-dose chemotherapy: longitudinal study with mr imaging and proton spectroscopy. AJNR 19 (1998) 217-221
7. Saykin A.J., Ahles T.A., and McDonald B.C. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiat 8 4 (2003) 201-216
8. Ahles T.A., Saykin A.J., Furstenberg C.T., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20 2 (2002) 485-493
9. Dietrich J., Han R., Yang Y., Mayer-Proschel M., and Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5 7 (2006) 22.1-22.23
10. Dietrich J., Han R., Yang Y., Mayer-Proschel M., and Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5 7 (2006) 18-19
11. Levokovitz Y., Gil-Ad I., Zeldich E., Dayag M., and Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines. J Mol Neurosci 27 1 (2005) 29-42
12. Nordenberg J., Fenig E., Landau M., Weizman R., and Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 58 (1999) 1229-1236
13. Cohen M.E., Dembling B., and Schorling J.B. The association between schizophrenia and cancer: a population based mortality study [abstract]. Schizophr Res 57 (2002) 139-146
14. Dalton S.O., Johansen C., Poulsen A.H., et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 95 (2006) 934-939
15. Mortensen B. The occurrence of cancer in first admitted schizophrenic patients [abstract]. Schizophr Res 12 (1994) 185-194
16. Gil-Ad I., Shtaif B., Levkovitz Y., Dayag M., Zeldich E., and Weizman A. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines. J Mol Neurosci 22 (2004) 189-198
17. + (GIRK) channels expressed in Xenopus oocytes. Br J Pharmacol 129 (2000) 1716-1722
18. Sunderland T., and Cohen B.M. Blood to brain distribution of neuroleptics [abstract]. Psychiat Res 20 4 (1987) 299-305
19. Gil-Ad I., Shtaif B., Shiloh R., and Weizman A. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cell Mol Neurobiol 21 6 (2001) 705-716
20. Gilles M., Deuschle M., Kellner S., et al. Paroxetine serum concentrations in depressed patients and response to treatment [abstract]. Pharmacopsychiatry 38 3 (2005) 118-121
21. Lucca A., Gentilini G., Lopez-Silva S., and Soldarini A. Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography [abstract]. Ther Drug Monit 22 3 (2000) 271-276
22. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 4 (2000) 428-438
23. Karson C.N., Newton J.E.O., Livingston R., et al. Human brain fluoxetine concentrations. J Neuropsychiat Clin Neurosci 5 (1993) 322-329
24. Munster P., Marchion D., Bicaku E., et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25 15 (2007) 1979-1985
25. McLachlan R.S. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci 14 (1987) 294-296
26. Papazian O., Canizales E., Alfonso I., Archila R., Duchowny M., and Aircardi J. Reversible dementia and apparent brain atrophy during valproate therapy. Ann Neurol 38 (1995) 687-691
27. Guerrini R., Belmonte A., Canapicchi R., Casalini C., and Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 39 1 (1998) 27-32
28. Rooprai H.K., Christidou M., and Pilkington G.J. The potential for strategies using micronutrients and heterocyclic drugs to treat invasive gliomas. Acta Neurochir 145 (2003) 683-690
29. Jacobs B.L., van Praag H., and Gage F.H. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiat 5 (2000) 262-269
30. Fuchs E., Czeh B., Kole M.H.P., Michaelis T., and Lucassen P.J. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol 14 (2004) S481-S490
31. Santarelli L., Saxe M., Gross C., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
32. Sairanen M., Lucas G., Ernfors P., Castren M., and Castren E. Brain derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 25 5 (2005) 1089-1094
33. Manev H., Uz T., Smalheiser N.R., and Manev R. Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. Eur J Pharmacol 411 (2001) 67-70
34. Brunnauer A., Laux G., Geiger E., Soyka M., and Moller H.J. Antidepressants and driving ability: results from a clinical study. J Clin Psychiat 67 11 (2006) 1776-1781
35. Fava M., Graves L.M., Benazzi F., et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiat 67 (2006) 1754-1759
36. Allen D., Curran H.V., and Lader M. The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects [abstract]. Eur J Clin Pharmacol 40 4 (1991) 355-362
37. Bartfai A., Asberg M., Martensson B., and Gustavsson G. Memory effects of clomipramine treatment: relationship to CSF monoamine metabolites and drug concentrations in plasma [abstract]. Biol Psychiat 30 11 (1991) 1075-1092
38. De Carvalho S.C., Marcourakis T., Artes R., and Gorenstein C. Memory performance in panic disorder patients after chronic use of clomipramine [abstract]. J Psychopharmacol 16 3 (2002) 220-226
39. Hager E.D., Dziabmor H., Hohmann D., Winkler P., and Strama H. Effects of lithium on thrombopoesis in patients with low platelet cell counts following chemotherapy or radiotherapy [abstract]. Biol Trace Elem Res 83 2 (2001) 139-148
40. Meredith EJ, Holder MJ, Chamba A, et al. The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics. FASEB J. [published on-line May 3, 2005; retrieved May 11, 2007].
41. International Network for Cancer Treatment and Research (INCTR) Report, Institut Pasteur; 2006. [retrieved May 11, 2007].
42. Crawford K.W., and Bowen W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 62 1 (2002) 313-322
43. Wei Z., Mouusseau D.D., Dai Y., Cao X., and Li X.M. Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS (abstract). Pharmacogenomics J 6 4 (2006) 279-288
44. Hashimoto K., and Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals [abstract]. Curr Pharm Des 12 30 (2006) 2857-3876